Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0K4TV
|
|||
Former ID |
DNC014689
|
|||
Drug Name |
5-Methyl-2-m-tolyl-1H-[1,8]naphthyridin-4-one
|
|||
Synonyms |
NSC676186; AC1L8OZL; CHEMBL317272; SCHEMBL7920133; CTK8D2147; ZINC5504116; NSC-676186; NCI60_026913; 5-methyl-2-(3-methylphenyl)-1,8-naphthyridin-4-ol; 5-methyl-2-(3-methylphenyl)-1H-1,8-naphthyridin-4-one
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C16H14N2O
|
|||
Canonical SMILES |
CC1=CC(=CC=C1)C2=CC(=O)C3=C(C=CN=C3N2)C
|
|||
InChI |
1S/C16H14N2O/c1-10-4-3-5-12(8-10)13-9-14(19)15-11(2)6-7-17-16(15)18-13/h3-9H,1-2H3,(H,17,18,19)
|
|||
InChIKey |
ZLZNSSZWWMBAMD-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Tubulin (TUB) | Target Info | Inhibitor | [1] |
Tubulin beta (TUBB) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Phagosome | |||
Gap junction | ||||
Pathogenic Escherichia coli infection | ||||
NetPath Pathway | FSH Signaling Pathway | |||
TCR Signaling Pathway | ||||
EGFR1 Signaling Pathway | ||||
Panther Pathway | Cytoskeletal regulation by Rho GTPase | |||
Huntington disease | ||||
Reactome | Regulation of PLK1 Activity at G2/M Transition | |||
Loss of Nlp from mitotic centrosomes | ||||
Recruitment of mitotic centrosome proteins and complexes | ||||
Loss of proteins required for interphase microtubule organization?from the centrosome | ||||
Anchoring of the basal body to the plasma membrane | ||||
WikiPathways | Parkin-Ubiquitin Proteasomal System pathway | |||
Pathogenic Escherichia coli infection | ||||
Mitotic G2-G2/M phases |
References | Top | |||
---|---|---|---|---|
REF 1 | Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubul... J Med Chem. 1997 Sep 12;40(19):3049-56. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.